[Better medicines for children].
The European Regulation incenting pharmaceutical companies to develop drugs in children will have substantial consequences for all partners involved. Children and parents will be asked to participate in clinical trials, paediatricians to monitor these investigations, industry to be creative and propose adapted formulations, ethical committees to deliver advices and public health authorities to assist the system in order to bring to a good end a full set of paediatric indications.